ALKBH5-IN-6
ALKBH5-IN-6 is an ALKBH5 inhibitor with an IC50 of 2.68 μM and a Kd of 5.78 μM. ALKBH5-IN-6 induces G2/M cell cycle arrest and Apoptosis, increases global RNA methylation levels, downregulates MCL-1, Bcl-xL, and TACC3 protein levels, and impairs cell self-renewal. ALKBH5-IN-6 exhibits anticancer activity against acute myeloid leukemia.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Formel: C18H14N2O6S
- Molecular Weight:386.38
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
ALKBH5 5.78 μM (Kd) |
Mcl-1 |
Bcl-xL |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MOLM-13 | IC50 |
4.96 μM
|
Antiproliferative activity against human MOLM-13 cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
Antiproliferative activity against human MOLM-13 cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
|
42913141 |
| Kasumi 1 | IC50 |
6.71 μM
|
Antiproliferative activity against human Kasumi-1 cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
Antiproliferative activity against human Kasumi-1 cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
|
42913141 |
| OCI-AML-3 | IC50 |
8.75 μM
|
Antiproliferative activity against human OCI-AML3 cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
Antiproliferative activity against human OCI-AML3 cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
|
42913141 |
| OPM-2 | IC50 |
5.50 μM
|
Antiproliferative activity against human OPM-2 cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
Antiproliferative activity against human OPM-2 cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
|
42913141 |
| NCI-H929 | IC50 |
7.09 μM
|
Antiproliferative activity against human NCI-H929 cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
Antiproliferative activity against human NCI-H929 cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
|
42913141 |
| PBMC | IC50 |
90.11 μM
|
Cytotoxicity against human PBMC#1 cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
Cytotoxicity against human PBMC#1 cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
|
42913141 |
| PBMC | IC50 |
116.40 μM
|
Cytotoxicity against human PBMC#2 cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
Cytotoxicity against human PBMC#2 cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
|
42913141 |
In Vitro
ALKBH5-IN-6 (0.63-80 µM; 72 h) exhibits ALKBH5-dependent cytotoxicity in MOLM-13 cells[1].
ALKBH5-IN-6 (20 µM; 7 days) impairs LSC self-renewal capacity in MLL-AF9 mouse AML cells, reducing LSC frequency to 1 in 83.2 cells[1].
The inhibitory effect of ALKBH5-IN-6 (2 µM) on ALKBH5 is attenuated by increasing 2-OG, supporting the involvement of the 2-OG pocket[1].
ALKBH5-IN-6 (0-20 µM) increases global m6A levels in MOLM-13 cells[1].
ALKBH5-IN-6 (0.31-10 µM) binds hALKBH5 with a KD of 5.78 µM in SPR[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:CRISPR/Cas9 ALKBH5-knockout MOLM-13 cells (sgALKBH5 #1 and #2)
-
Concentration:0.63, 1.25, 2.50, 5.0, 10, 20, 40, and 80 µM
-
Incubation Time:72 h
-
Result:Cytotoxicity was markedly attenuated in ALKBH5-deficient MOLM-13 cells (sgALKBH5 #1 and sgALKBH5 #2) relative to sgControl cells.
-
Cell Line:MOLM-13 cells
-
Concentration:0, 5.0, 10.0 µM
-
Incubation Time:24 h
-
Result:G1 decreased from 67.33% to 48.11%, G2 increased from 4.71% to 12.30%, and S increased from 27.97% to 39.59% at 10 µM.
-
Cell Line:MOLM-13 cells
-
Concentration:0, 5.0, 10.0, and 20.0 µM
-
Incubation Time:24 h
-
Result:Dose-dependently promoted apoptosis in MOLM-13 cells, with the Q2 population increasing from 5.92% at 0 µM to 49.1% at 20 µM.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:MOLM-13 subcutaneous xenograft model[1]
-
Dosage:20 mg/kg
-
Administration:i.p.; once daily; 9 days
-
Result:After 9 days of administration, tumor volume and tumor weight were reduced relative to the vehicle group.
No obvious body weight changes were observed in mice.
Chemical Information
-
Molecular Weight 386.38
-
Formel C18H14N2O6S
-
SMILES
O=S(C1=CC=C(N2C(C=CC2=O)=O)C=C1)(NC3=CC=CC(C(OC)=O)=C3)=O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Keywords
- ALKBH5-IN-6
- Anaplastic lymphoma kinase (ALK)
- Apoptosis
- DNA/RNA Synthesis
- Bcl-2 Family
- Anaplastic lymphoma kinase
- ALK tyrosine kinase receptor
- CD246
- Cluster of differentiation 246
- ALKBH5
- Bcl-xL
- G2/M phase cell cycle arrest
- MCL-1
- RNA demethylase
- RNA methylation
- TACC3
- acute myeloid leukemia
- alpha-ketoglutarate
- apoptosis
- leukemic stem cell self-renewal
- Inhibitor
- inhibitor
- inhibit